Pharmaresearch Bio Co (XKRX:217950) Change In Receivables : ₩-302 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Pharmaresearch Bio Co Change In Receivables?

Pharmaresearch Bio Co's change in receivables for the quarter that ended in Dec. 2023 was ₩-302 Mil. It means Pharmaresearch Bio Co's Accounts Receivable increased by ₩302 Mil from Dec. 2022 to Dec. 2023 .

Pharmaresearch Bio Co's change in receivables for the fiscal year that ended in Dec. 2023 was ₩-302 Mil. It means Pharmaresearch Bio Co's Accounts Receivable increased by ₩302 Mil from Dec. 2022 to Dec. 2023 .

Pharmaresearch Bio Co's Accounts Receivable for the quarter that ended in Dec. 2023 was ₩367 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Pharmaresearch Bio Co's Days Sales Outstanding for the six months ended in Dec. 2023 was 3.34.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Pharmaresearch Bio Co's liquidation value for the six months ended in Dec. 2023 was ₩12,121 Mil.

Pharmaresearch Bio Co Change In Receivables Historical Data

The historical data trend for Pharmaresearch Bio Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaresearch Bio Co Change In Receivables Chart

Pharmaresearch Bio Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

48.92

-743.33

221.53

23.03

-302.33

Pharmaresearch Bio Co Semi-Annual Data
	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Change In Receivables	Get a 7-Day Free Trial			48.92	-743.33	221.53	23.03	-302.33

Pharmaresearch Bio Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-302 Mil.

Pharmaresearch Bio Co (XKRX:217950) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Pharmaresearch Bio Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	366.8	/	20030.641	*	91
=	3.34

2. In Ben Graham's calculation of liquidation value, Pharmaresearch Bio Co's accounts receivable are only considered to be worth 75% of book value:

Pharmaresearch Bio Co's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	40091.702	-	29510.703	+	0.75 * 366.8	+	0.5 * 2529.812
=	12,121

Pharmaresearch Bio Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Pharmaresearch Bio Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaresearch Bio Co (XKRX:217950) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

641-3, Saimdang-ro, Gangwon-do, Gangneung-si, KOR, 13494

Website

http://www.pr-bio.co.kr

Pharmaresearch Bio Co Ltd is a Korea-based biopharmaceutical company. The company is engaged in the research and development, manufacturing, sale, and marketing of biopharmaceutical products. Its product is ReNTox Injections, and Clostridium Botulinum Toxin type A is in pipeline.

Pharmaresearch Bio Co (XKRX:217950) Headlines

No Headlines